Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus

Fabiola Justina Fumero León1 | Lucas Lima da Silva2 | Alanna Calheiros Santos2 | Vanessa Duarte da Costa2 | Juliana Custódio Miguel2 | Julia Trece Marques2 | Giselle Prado Nascimento2 | Elisangela Ferreira da Silva2 | Lia Laura Lewis-Ximenez2 | Livia Melo Villar2 | Vanessa Salete de Paula1

1Laboratory of Molecular Virology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
2Laboratory of Viral Hepatitis, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

Correspondence
Vanessa Salete de Paula, Laboratory of Molecular Virology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, 4365, Brazil Av., Manguinhos, Rio de Janeiro – RJ, 21040-360, Brazil.
Email: vdepaula@ioc.fiocruz.br

Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can generate a systemic inflammatory response, characterized by a cytokine storm and associated with an exaggerated release of proinflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-17, all of which can affect the liver. Here, we aimed to evaluate the cytokine profiles of patients suffering from coronavirus disease (COVID)-19 and/or hepatitis. We subjected 87 patients to serology and/or polymerase chain reaction analysis for the hepatitis C virus. They were also tested for TNF-α, IL-6, and IL-17 using commercial immunoassay kits. The test results of the COVID-19/hepatitis patients (n = 8) were compared with that of the negative controls (n = 28), hepatitis C patients (n = 29), and COVID-19 patients (n = 22). All COVID-19 patients (mono- and coinfectected) expressed high levels of cytokines. The COVID-19/hepatitis patients exhibited higher levels of IL-6 (6.33 ± 3.9 pg/ml) and IL-17 (102.23 ± 2.7 pg/ml); however, TNF-α values were lower (68.08 ± 15.88 pg/ml), as compared with that of the hepatitis patients (p < 0.001), and lower than that of the COVID-19 patients and exceptionally for TNF-α (p < 0.05). These data highlight the importance of monitoring patients with hepatitis and COVID-19.

KEYWORDS
COVID-19, cytokines, hepatitis, IL-6, IL-17, TNF-α

1 | INTRODUCTION

Studies have shown that patients infected with severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 develop different degrees of liver damage,1 including changes in the coagulation profile and increased levels of liver enzymes. However, the extent of liver damage has not yet been established, especially in patients with previous hepatic impairments, like liver injury due to viral hepatitis. Recent studies have demonstrated that liver damage occurs in approximately 60% of patients infected with SARS-CoV-2.2 In fact, the proportion of liver damage is significantly higher in patients with severe COVID-19 than in the mild cases; moreover, in cases of death due to COVID-19, liver damage has been observed in 28%–30% of the patients.3 Incidentally, the biochemistry profile report of COVID-19 patients published by the World Gastroenterology
Organization (2021) mentions that an asymptomatic elevation of the liver enzymes, as detected in 14%–16% of the studied cases, is the most common observation. In fact, in >50% of the patients analyzed, there was an increase in alanine transferase (ALT) and aspartate aminotransferase (AST), along with a significant elevation of gamma-glutamyl transferase (GGT). Moreover, there was a slight elevation in the total bilirubin (TB) in 10% of the patients, while the alkaline phosphatase enzyme was typically in the normal range in mild cases of COVID-19. As compared with the severe COVID-19 cases, the liver enzymes were less elevated in the mild cases of the disease, only up to three times the value of the upper normal limit. In fact, among the studied patients, the serum AST levels were >40 IU/L in 52% of the patients who progressed to death and only in 16% of the ones who progressed satisfactorily. In general, changes in AST are more frequent, as compared with the changes in ALT in the severe patients. Incidentally, hepatitis C virus (HCV) infection has a worldwide distribution, but the majority of the individuals infected with HCV remain asymptomatic, that is, they do not develop the acute form of the disease. Moreover, among the small percentage of acute hepatitis C cases, approximately 30% are cured spontaneously within 6 months, while the remaining 70% develop into the chronic form of the disease, which is associated with a high risk of liver cirrhosis and hepatocellular carcinoma. Several theories have been proposed to explain the pathophysiology of SARS-CoV-2 and HCV coinfection. These include the intrinsic tropism of the virus for hepatocytes and bile ducts that may occur as a direct consequence of the complex humoral immune responses in these patients. Alternatively, it may be an indirect response to the cytokine storm, that is, the exaggerated production of proinflammatory cytokines during COVID-19. In fact, the latter theory is highly relevant, and it may be the key factor in the development and evolution of the clinical and laboratory disease profiles for SARS-CoV-2 and HCV coinfection. Recent studies have reported a high production of proinflammatory cytokines in severe clinical cases of SARS-CoV-2 infection; additionally, the increased levels of IL-6, tumor necrosis factor-α (TNF-α), IL17A, IL-10, and interleukin-2 receptor (IL-2R) in patients diagnosed with chronic liver disease may associate the cytokine storm with the severity of COVID-19 in this group of patients. In the present study, we evaluated the immunological profiles of COVID-19 patients, with and without liver changes, as well as patients suffering from only hepatitis C.

2 MATERIALS AND METHODS

The enzymatic and immunological profiles of eight patients suffering from both acute COVID-19 and chronic hepatitis C were compared with the corresponding profiles of 28 healthy subjects (i.e., negative for both diseases), 22 patients with acute COVID-19, and 29 patients with chronic hepatitis C. The inclusion criteria for the study were: minimum age of 18 years, confirmed clinical and laboratory diagnosis (quantitative reverse transcription-polymerase chain reaction [RT-qPCR]) for COVID-19 and serology (anti-HCV reagent) and/or molecular diagnosis (HCV RNA detection) for hepatitis C, and signing the consent form. Blood and nasopharyngeal swab samples were collected to perform the necessary tests. The blood samples were used to determine the levels of ALT, AST, GGT, alkaline phosphatase, BT, indirect bilirubin (IB), and direct bilirubin (DB). Additionally, the complete blood count and platelet count were also evaluated. The ALT and AST levels were determined by UV-IFCC kinetics using Labmax Plenno equipment (Labtest, MG). Serum concentrations of GGT and alkaline phosphatase were determined using colorimetric methods (Labtest, MG). The concentrations of cytokines IL-6, IL-17, and TNF-α were evaluated using enzyme-linked immunosorbent assay (ELISA) kits (Peprotech TMB ELISA Development Kit), according to the manufacturer’s instructions. All samples were stored in ultra-freezer at −80°C and the samples were defrosted and directly tested to cytokines.

The SARS-CoV-2 RNA was extracted from nasopharyngeal swab samples (by Qiagen commercial kit) and quantified using TaqMan RT-qPCR assay (AgPath-ID One-Step RT-PCR; Thermo Fisher Scientific). A set of different oligonucleotides and probes were used to detect the SARS-CoV-2 RNA. Descriptive statistical analysis was performed by calculating the means and frequencies of the test results, and the possible relationships between categorical variables were evaluated using χ² or Fisher’s exact test, whichever was applicable. Statistical significance was set at p < 0.05. Statistical analyses were performed using GraphPad Software Prism (version 9.0).

3 RESULTS

We observed that the liver enzymes of the patients suffering from only hepatitis were higher than the normal reference values but lower than the expected thresholds for chronic HCV infection [AST: 79.12 (SD: 34.43); ALT: 48.08 (SD: 48.08), and GGT: 109.7 (SD: 109.7)] (Table 1). The cytokine values for these patients were: IL-6: 1.124 (SD: 0.07); IL-17: 82.45 (SD: 10.22); and TNF-α: 104.2 (SD: 6.18). Among the 87 enrolled individuals, 9.2% (8) were positive for hepatitis C as well as COVID-19 (confirmed by RT-qPCR), and out of them, 62.5% were females (5) and 37.5% (3) were males with a mean age of 55 ± 5 years. For the COVID-19/hepatitis C patient group, there was no significant increase in the AST [27.50 (SD: 10.07)] and ALT [37.38 (SD: 37.38)] values, as compared with the normal reference values. However, the mean value of GGT was high [103.3 (SD: 103.3)]. The mean cytokine values for these patients were: IL-6: 6.226 (SD: 4.00); IL-17: 102.4 (SD: 2.76); and TNF-α: 67.50 (SD: 17.79) (Table 1). Among the 87 enrolled individuals, 75.86% (66) tested positive for the SARS-CoV-2 RNA (detected by RT-qPCR), and they were classified into the COVID-19 group. In this group, 65.45% of the patients were men (12) and 45.45% were women (10), with an average age of 35 ± 15 years. Majority of them self-declared to be of white ethnicity (36.36%). Interestingly, the enzymatic profile of this group was within the normal reference range.

Incidentally, the mean values of the liver enzymes AST, ALT, and GGT were the highest in the group of patients mono-infected with
On the contrary, the liver enzymes of the COVID-19/HCV coinfectected patients were within the normal reference values. Moreover, the SARS-CoV-2 mono-infected patients had lower levels of liver enzymes, as compared with that of the other two patient groups (Figure 1). With respect to the cytokine profiles, we did not record any increase in the mean values of IL-6 or IL-17 in the mono-infected HCV group, as compared with that of the control group. However, these patients expressed a higher mean value of TNF-α, as compared

**Table 1** Demographics and laboratory test results of study subjects (Rio de Janeiro, 2021)

|                  | Control, N (%) | COVID-19, N (%) | COVID-19/Hepatitis, N (%) | Hepatitis, N (%) |
|------------------|----------------|-----------------|---------------------------|------------------|
| Sample size      | 28 (32.18)     | 22 (25.29)      | 8 (9.2)                   | 29 (33.33)       |
| Gender           |                |                 |                           |                  |
| Male             | 18 (64.29)     | 12 (54.55)      | 3 (37.5)                  | 12 (41.38)       |
| Female           | 10 (35.71)     | 10 (45.45)      | 5 (62.5)                  | 16 (55.17)       |
| Age (years)      | 50 ± 4         | 35 ± 15         | 55 ± 5                    | 50 ± 5           |
| Skin color       |                |                 |                           |                  |
| Black            | 11 (39.29)     | 2 (9.1)         | 0                         | 6 (20.70)        |
| Multiracial      | 3 (10.71)      | 6 (27.27)       | 4 (50)                    | 2 (6.89)         |
| White            | 14 (50)        | 8 (36.36)       | 4 (50)                    | 6 (20.70)        |
| Enzymes (UI/L)   | Mean (SD)      | Mean (SD)       | Mean (SD)                 | Mean (SD)       |
| AST<sup>a</sup>  | 1.724 (2.52)   | 21.29 (9.98)    | 27.50 (10.07)             | 79.12 (34.43)<sup>b</sup> |
| ALT<sup>a</sup>  | 6.692 (8.98)   | 26.94 (20.43)   | 37.38 (37.38)             | 48.08 (48.08)<sup>b</sup> |
| GGT<sup>a</sup>  | 26.92 (20.26)  | 46.82 (50.23)   | 103.3 (103.3)             | 109.7 (109.7)<sup>b</sup> |
| Fibrosis-4 (FIB-4) |                |                 |                           |                  |
| <1.45            | 15             | 5               |                          |                  |
| <3.25 or >1.45   | 1              | 4               |                          |                  |
| >3.25            | 28             | 7               | 2                         | 15               |
| Cytokines (pg/ml) |                |                 |                           |                  |
| IL-6             | 1.724 (2.52)   | 16.37 (12.17)   | 6.226 (4.00)              | 1.124 (0.07)     |
| IL-17            | 82.83 (11.51)  | 115.0 (11.08)   | 102.4 (2.76)              | 82.45 (10.22)    |
| TNF-α            | 11.04 (7.90)   | 103.6 (50.02)   | 67.50 (17.79)             | 104.2 (6.18)     |
| Nasal swab       |                |                 |                           |                  |
| CT N1            | ND             | CT (±SD)        | CT (±SD)                  |                  |
| CT N2            | ND             | 30.75 (6.39)    | 28.70 (7.68)              | ND               |
| CT E             | ND             | 30.68 (6.68)    | 29.72 (8.73)              | ND               |
| Oropharyngeal swab |               |                 |                           |                  |
| CT N1            | ND             | 29.13 (6.41)    | 26.67 (7.97)              | ND               |
| CT N2            | ND             | 28.85 (6.90)    | 27.74 (9.47)              | ND               |
| CT E             | ND             | ND              | ND                        | ND               |

Note: Nonparametric tests were used to analyze the differences among the mean values of IL-6, IL-17, TNF-α, AST, ALT, and GGT of the groups (p < 0.05). Abbreviations: ALT, alanine transferase; AST, aspartate aminotransferase; C<sub>t</sub>, cycle threshold; E, SARS-CoV-2 envelope genome; GGT, gamma-glutamyltransferase; IL-6, interleukin-6; IL-17, interleukin-17; N, sample; N1 and N2, nucleocapsid, ND, not detected; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation; TNF-α, tumor necrosis factor-α.

<sup>a</sup>ALT reference value: 7–55 U/L, AST reference value: 8–48 U/L, and GGT reference value: 8–61 U/L.

<sup>b</sup>ALT reference value for chronic hepatitis: <31 U/L (female) and <41 U/L (male), AST reference value for chronic hepatitis: <31 U/L (female) and 37 U/L (male), and GGT reference value for chronic hepatitis: 8–61 U/L (male) and 5–36 U/L (female).
with that of the control group (Figure 2). Incidentally, the COVID-19/hepatitis C patient group showed an increase in the cytokine levels, as compared with that of the control group. However, in comparison with the mono-infected HCV group, these patients showed an increase in IL-6 and IL-17, but not for TNF-α. On the contrary, the COVID-19 patient group showed increased values for both IL-6 and IL-17, but lower for TNF-α, as compared with the COVID-19/hepatitis C and only hepatitis C group where higher levels of TNF-α were observed. Hence, a significant increase ($p < 0.05$) in the serological levels of IL-6, IL-17 was observed in the COVID-19 and COVID-19/hepatitis C patient groups, and this differs for TNF-α levels as compared with mono-infected hepatitis and control groups (Figure 2).

4 | DISCUSSION

Despite the limited availability of data regarding the clinical and laboratory studies of COVID-19 and hepatitis C coinfection, some reports indicate a strong association between chronic HCV infection and a significant rise in the serum concentrations of liver enzymes AST, ALT, and GGT, which serve as inflammatory indicators of the liver and biliary tract. Moreover, there is a possible relationship between the exaggerated systemic inflammatory response or cytokine storm that may occur during COVID-19 immune responses and the poor disease outcome in some groups of patients. Indeed, some studies have revealed a noticeable elevation of proinflammatory cytokines, such as IL-2, IL-6, TNF-α, and so forth in the plasma of COVID-19 patients. Similarly, in this study, we observed high cytokine levels in the COVID-19 patient group. Interestingly, in the COVID-19/hepatitis C patient group, the mean cytokine values were lower than that of the COVID-19 group, but the IL-6 and IL-17 were significantly higher than that of the hepatitis C group. Therefore, SARS-CoV-2 and HCV coinfection seem to modulate the cytokine immune response. Cycle threshold ($C_t$) values <40 were considered positive. In the COVID-19/hepatitis C group, we observed lower $C_t$ values than those reported in previous studies, thereby suggesting a higher viral load. Recent studies reveal an association between high viral load and the severity of the disease. In particular, in the SARS-CoV-2/HCV coinfected patients, a prolonged RNA shedding was observed, thereby increasing their chances of developing severe immune suppression. Hence, in comparison with the non-HCV-infected patients, the ones with SARS-CoV-2/HCV coinfection had a higher viral load and a delayed recovery from the disease. This should be considered while determining the isolation period and care measures for the SARS-CoV-2-infected patients.

The FIB-4 index enabled the correct identification of patients with severe fibrosis (F3–F4) and cirrhosis. In this study, all HCV patients had chronic diseases and most of them, that have data available, had fibrosis >3.25, which means a positive predictive value to confirm the existence of significant fibrosis (F3–F4). Most of the patients with hepatitis and COVID-19 had Fibrosis Score <1.45. However, a recent study, that included 125 patients with chronic hepatitis C and COVID-19 coinfection, showed that patients with liver cirrhosis are susceptible to higher severity and mortality if infected with COVID-19.

Studies of COVID-19 have shown a strong upregulation with and increased release of some proinflammatory cytokines such as IL-6, IL-17, TNF-α, IL-2, IL-10, and others. This has been associated with the hyperinflammatory phenomenon known as cytokine storm; in fact, one of the main features of the acute respiratory distress syndrome (ARDS) during the cytokine storm is a systemic dysregulated
inflammatory response as a result of the high expression of the aforementioned cytokines, which leads to aggravating the respiratory damages and multiorgan failure, including the liver.\textsuperscript{18} Even though IL-6, IL-17, and TNF-\(\alpha\) are not specific to SARS-CoV-2 nor of HCV or any other virus infection, studies in animals and clinical trials have demonstrated a significant increase in the production of cytokines, especially IL-6, IL-17A, IL-10, IL-2, TNF-\(\alpha\), and interferons in association with SARS-CoV-2 infection.\textsuperscript{19} Some clinical studies have demonstrated a positive correlation with high levels of IL-17A in association with more severe forms of COVID-19, developing diffuse alveolar damage with an increase of neutrophils and proteins leading to edema in the alveolar space. The IL-17, which operates “upstream” of both IL-1 and IL-6 and results in a reduction of neutrophil recruitment, several factors known to play major roles in ARDS would be inhibited.\textsuperscript{20} Furthermore, increased inflammatory cytokines (such as tumor necrosis factor-\(\alpha\) [TNF-\(\alpha\)] and interleukin-6 [IL-6]) are observed in COVID-19 patients, especially in the severe group.\textsuperscript{21} In conclusion, our observations demonstrate a significant increase in the serological levels of IL-6, IL-17 and interesting results of TNF-\(\alpha\) in the SARS-CoV-2-infected patients; additionally, coinfection with HCV needs to be more investigated to further modulate the immune response. The results of this study are relevant since it is important to collect information about the co-occurrence of COVID-19 and hepatitis. Future studies should measure IL-10, IL-2, and IL-4 and use a larger sample size to understand the regulatory mechanisms of the systemic inflammation and liver injury involved in hepatitis patients with COVID-19. This will further help to elucidate the relevant aspects of the inflammatory process that is necessary for monitoring post-COVID infections in patients with previous liver disorders.

**ACKNOWLEDGMENTS**

This study was financed by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES; Finance Code 001), Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), INOVA Oswaldo Cruz Foundation and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

**CONFLICT OF INTERESTS**

The authors declare that there are no conflict of interests.

**ETHICS STATEMENT**

This study was approved by Oswaldo Cruz Foundation ethical committee CAAE 30468620.5.0000.5248 approval number 4.112.243. All patients provided written informed consent.

**AUTHOR CONTRIBUTIONS**

Performed the experiments, analyzes and interpretation of the data, draft of the article, final approval of the version to be published in accordance with all aspects of the work: Fabiola Justina Fumero León. Sample collection, interviewing the patients, performed the experiments, data acquisition and final approval of the version to be published in accordance with all aspects of the work: Lucas Lima da Silva, Alanna Calheiros Santos, Vanessa Duarte da Costa, Juliana Custódio Miguel, Julia Trece Marques, Giselle Prado Nascimento, Elisangela Ferreira da Silva. Follow up the clinical status of the patients, final approval of the version to be published in accordance with all aspects of the work: Lia Laura Lewis-Ximenez. Wrote the project, study conception and design, analyzes and interpretation of the data, draft of the article, critical revision of the article, final approval of the version to be published in...
accordance with all aspects of the work: Livia Melo Villar and Vanessa Salete de Paula.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES
1. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020;382(18):1708-1720.
2. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.
3. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.
4. Hamid S, Alvares da Silva MR, Burak KW, et al. WGO guidance for the care of patients with COVID-19 and liver disease. J Clin Gastroenterol. 2021;55(1):1-11.
5. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;2020(2):47-52.
6. Marjot T, Webb GJ, Barritt AS, et al. COVID-19 and liver disease: mechanistic and clinical perspective. Nat Rev Gastroenterol Hepatol. 2021;18:348-364.
7. Brito CA, Barros FM, Lopes EP. Mechanisms and consequences of COVID-19 associated liver injury: what can we affirm? World J Hepatol. 2020;12(8):413-422.
8. CDC (Centers for Disease Control and Prevention). Disponível em. junho 2021. https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primerprobes.html/
9. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):1-8. doi:10.2807/1560-7917.ES.2020.25.3.2000045
10. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;1(3):367-379
11. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. United European Gastroenterol J. 2020;8(5):509-519.
12. Kim JS, Lee JY, Yang JW, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316-329.
13. Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123-1130.
14. Afify M, Hamza AH, Alomari RA. Correlation between serum cytokines, interferons and liver functions in hepatitis C virus patients. J Interferon Cytokine Res. 2017;37(1):32-38.
15. Silva J. Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality. medRxiv. 2021. doi:10.1101/2021.01.04.21249236
16. Villar LM, Paula VS, Pinto LCM, et al. Clinical and laboratory characteristics of hepatitis C and COVID-19 coinfection: prolonged RNA shedding in nonhospitalized cases. Clin Case Rep. 2021;9(8):e8645.
17. Afify S, Eysa B, Hamid FA, et al. Survival and outcomes for co-infection of chronic hepatitis C with and without cirrhosis and COVID-19: a multicenter retrospective study. World J Gastroenterol. 2021;27(42):7362-7375.
18. Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66-70.
19. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-108.
20. Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol. 2020;20(6):345-346. doi:10.1038/s41577-020-0328-z
21. Chen XY, Yan BX, Man XY. TNFa inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis. Ther Adv Respir Dis. 2020;14:1753466202926800. doi:10.1177/1753466202926800

How to cite this article: León FJF, da Silva LL, Santos AC, et al. Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus. J Med Virol. 2022;94:2296-2301. doi:10.1002/jmv.27614